BioPharmX Corporation completed their last subject visit in a Phase 2b trial of their investigational acne drug, BPX-01, and the last site close-out visit was April 7, 2017.
The company now plans to announce topline data from the trial in the first half of May.
BPX-01 is a hydrophilic topical gel with fully solubilized minocycline that can penetrate the skin to deliver the antibiotic to where acne develops in the pilosebaceous unit.
The Phase 2b study was a dose-finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, double-blind, three-arm, vehicle-controlled study involves 225 individuals, aged 9 to 40, who have moderate-to-severe inflammatory, non-nodular acne vulgaris.
The company expects to present complete data from the trial to the medical community at Alabama Dermatology Society's Dermatology Summer Symposium, June 22-25, in Sandestin, Fla.